VERTEX PHARMACEUTICALS INC / MA (VRTX) Gross margin 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
86.2%FY2025 · since FY2016: 87.6% → 86.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 86.2% | +0.1 pp |
| FY2024 | 86.1% | -1.1 pp |
| FY2023 | 87.2% | -0.7 pp |
| FY2022 | 87.9% | -0.2 pp |
| FY2021 | 88.1% | -0.1 pp |
| FY2020 | 88.1% | +1.3 pp |
| FY2019 | 86.8% | +0.3 pp |
| FY2018 | 86.6% | -2.4 pp |
| FY2017 | 88.9% | +1.3 pp |
| FY2016 | 87.6% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Operating incomeVRTX Operating marginVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →